



## Company Overview

Fortress Biotech, Inc. ("Fortress") is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has eight marketed prescription pharmaceutical products and multiple programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress' portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress' model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company's portfolio of product opportunities. Fortress has established partnerships with some of the world's leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children's Hospital and Sentyln. For more information, visit [www.fortressbiotech.com](http://www.fortressbiotech.com).

## Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Jan 13 2026, 7:45 AM EST

## Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

Dec 15 2025, 8:00 AM EST

## Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Dec 10 2025, 8:30 AM EST

## Management Team

### Lindsay A. Rosenwald, M.D.

Chairman, President and Chief Executive Officer

### Michael S. Weiss

Executive Vice Chairman, Strategic Development

### David Jin

Chief Financial Officer and Head of Corporate Development

### Samuel Berry

General Counsel and Corporate Secretary

## Fortress Biotech, Inc.

1111 Kane Concourse  
Suite 301  
Bay Harbor Islands, FL 33154

## Stock Overview

Symbol	FBIO	Jaclyn Jaffe
Exchange	Nasdaq	Nicole McCloskey
Market Cap	110.1m	T: 781-652-4500
Last Price	\$3.48	<a href="mailto:ir@fortressbiotech.com">ir@fortressbiotech.com</a>
52-Week Range	\$1.32 - \$4.53	

## Investor Relations

## **Disclaimer**

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.